Opportunity Information: Apply for HRSA 15 079
Apply for HRSA 15 079
- The Health Resources and Services Administration in the health sector is offering a public funding opportunity titled "Cooperative Agreements to Support Comprehensive Medical Care for Thalassemia" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.110 Maternal and Child Health Federal Consolidated Programs.
- This funding opportunity was created on Dec 23, 2014 and posted on Dec 23, 2014.
- Applicants must submit their applications by Feb 23, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $615,000.00 to eligible and selected applicants.
- The number of recipients for this funding is limited to 4 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification) Native American tribal organizations (other than Federally recognized tribal governments).
- As cited in 42 CFR Part 51 a.3(a), any public or private entity, including an Indian Tribe or Tribal organization (as those terms are defined in 25 U.S.C. 450b), is eligible to apply for this Federal funding opportunity. Applicants are not allowed to apply for both Projects.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Health Resources and Services Administration (HRSA), through the Maternal and Child Health Bureau (MCHB), offered a discretionary cooperative agreement opportunity (HRSA-15-079) to strengthen comprehensive medical care for people with thalassemia under the National Hereditary Blood Disorders Programs authority in section 501(a)(2) of the Social Security Act (42 U.S.C. 701(a)(2)). The central purpose was a time-limited demonstration project aimed at two practical outcomes: improving how individuals with thalassemia are identified and improving their access to high-quality medical services, especially for those who require ongoing treatment such as transfusion management and related complication monitoring.
The program was built around coordinated work between regionally focused awardees and one national-level partner. Together, awardees were expected to develop and sustain a national approach to understanding who is affected by thalassemia and what services they need, with the broader intent of assuring access to comprehensive care. A major deliverable was collaboration with stakeholders to propose a model protocol for improving thalassemia care delivery, including guidance on transfusion therapy, disease-specific screening practices, and consistent monitoring and treatment of therapy-related side effects, particularly iron overload. Beyond clinical protocols, the opportunity emphasized access: expanding specialty provider availability for thalassemia patients through strategies such as thalassemia treatment center networks, telehealth, and other coordinated referral and network models. It also highlighted the importance of primary care access so that patients can receive routine, non-disease-specific care (general health needs) alongside specialty hematology services.
Applicants had to choose one of two distinct projects and could not apply to both. Project 1, the Thalassemia Regionalized Collaborative Approach, was designed to fund up to three organizations to lead regional collaborative efforts that improve thalassemia care. HRSA expected to make roughly $540,000 available per year for Project 1 in total, with an application ceiling of up to $180,000 per awardee per year. Project 2, the National Level Partner, was intended to fund a single organization to support national coordination and partnership functions, with about $75,000 available per year and a ceiling of up to $75,000 per year. Both Project 1 and Project 2 were cooperative agreements, meaning HRSA anticipated substantial federal involvement and ongoing collaboration with recipients rather than a purely hands-off grant structure. Each project had a two-year project period.
Eligibility was broad: under 42 CFR Part 51a.3(a), any public or private entity could apply, including Indian Tribes or Tribal organizations as defined in 25 U.S.C. 450b, and other eligible applicants as described in the funding notice. There was no cost sharing or matching requirement. The opportunity was posted on December 23, 2014, with an original and current closing date of February 23, 2015, and it was later archived on April 24, 2015. HRSA anticipated making four total awards across both projects, with an estimated total funding amount of $615,000.
For administrative reference, the opportunity fell under CFDA 93.110 (Maternal and Child Health Federal Consolidated Programs) and used the cooperative agreement funding instrument within the health activity category. The funding announcement listed HRSA Grants Application Center support and provided a program contact, Edward Donnell Ivy, M.D., M.P.H., for questions about the announcement and access to materials.
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This opportunity was a discretionary cooperative agreement from the Health Resources and Services Administration (HRSA), through the Maternal and Child Health Bureau (MCHB), under the National Hereditary Blood Disorders Programs authority (section 501(a)(2) of the Social Security Act, 42 U.S.C. 701(a)(2)). It was identified as HRSA-15-079 and focused on strengthening comprehensive medical care for people with thalassemia.
What was the main purpose of HRSA-15-079?
The central purpose was a time-limited demonstration project aimed at two practical outcomes: (1) improving how individuals with thalassemia are identified, and (2) improving access to high-quality medical services, especially for people who require ongoing treatment such as transfusion management and monitoring for complications.
What outcomes did HRSA want the program to achieve?
The program emphasized improving identification of individuals with thalassemia and improving access to comprehensive, high-quality medical care. It particularly highlighted ongoing treatment needs (for example, transfusion therapy) and related complication monitoring (for example, therapy-related side effects such as iron overload).
What is meant by a "time-limited demonstration project" in this announcement?
In this context, it refers to a project designed to operate for a defined period (a two-year project period) to demonstrate practical improvements in thalassemia identification and access to comprehensive care, rather than an open-ended, indefinite program.
How was the program structured (regional and national roles)?
The program was built around coordinated work between regionally focused awardees and one national-level partner. Together, awardees were expected to develop and sustain a national approach to understanding who is affected by thalassemia and what services they need, with the broader intent of assuring access to comprehensive care.
What was a major deliverable expected from awardees?
A major deliverable was collaboration with stakeholders to propose a model protocol for improving thalassemia care delivery. This included guidance on transfusion therapy, disease-specific screening practices, and consistent monitoring and treatment of therapy-related side effects, particularly iron overload.
Did the opportunity address both specialty and primary care access?
Yes. In addition to strengthening specialty thalassemia services (such as hematology and transfusion management), the opportunity also highlighted the importance of primary care access so that patients can receive routine, non-disease-specific care alongside specialty services.
What strategies were encouraged to expand access to thalassemia specialty care?
The announcement emphasized expanding specialty provider availability through strategies such as thalassemia treatment center networks, telehealth, and other coordinated referral and network models.
What were the two project options applicants could choose from?
Applicants had to choose one of two distinct projects:
- Project 1: Thalassemia Regionalized Collaborative Approach (regional collaborative efforts to improve thalassemia care)
- Project 2: National Level Partner (national coordination and partnership functions)
Could an organization apply for both Project 1 and Project 2?
No. Applicants had to choose one of the two projects and could not apply to both.
How many awards were expected under Project 1?
Project 1 was designed to fund up to three organizations to lead regional collaborative efforts that improve thalassemia care.
How much funding was available for Project 1?
HRSA expected to make roughly $540,000 available per year for Project 1 in total, with an application ceiling of up to $180,000 per awardee per year.
How many awards were expected under Project 2?
Project 2 was intended to fund a single organization to serve as the National Level Partner.
How much funding was available for Project 2?
About $75,000 per year was available for Project 2, with a ceiling of up to $75,000 per year.
What is the total estimated funding and number of awards for the entire opportunity?
HRSA anticipated making four total awards across both projects, with an estimated total funding amount of $615,000.
What type of funding instrument was used?
Both Project 1 and Project 2 used a cooperative agreement funding instrument.
What does it mean that these awards were "cooperative agreements"?
It means HRSA anticipated substantial federal involvement and ongoing collaboration with recipients, rather than a purely hands-off grant structure.
How long was the project period?
Each project had a two-year project period.
Who was eligible to apply?
Eligibility was broad. Under 42 CFR Part 51a.3(a), any public or private entity could apply, including Indian Tribes or Tribal organizations as defined in 25 U.S.C. 450b, and other eligible applicants as described in the funding notice.
Was cost sharing or matching required?
No. There was no cost sharing or matching requirement.
When was the opportunity posted and when did it close?
The opportunity was posted on December 23, 2014. The original and current closing date was February 23, 2015.
Is this funding opportunity still open?
No. It was later archived on April 24, 2015.
What is the CFDA number associated with this opportunity?
The opportunity fell under CFDA 93.110 (Maternal and Child Health Federal Consolidated Programs).
What federal agency and bureau administered this opportunity?
The opportunity was administered by HRSA, through the Maternal and Child Health Bureau (MCHB).
What activity category did this opportunity fall under?
The funding instrument was a cooperative agreement within the health activity category.
Who could applicants contact with questions about the announcement?
The announcement listed a program contact for questions about the announcement and access to materials: Edward Donnell Ivy, M.D., M.P.H.
Was there application support mentioned?
Yes. The funding announcement listed HRSA Grants Application Center support.
What kinds of clinical issues were specifically highlighted for thalassemia care improvement?
The opportunity specifically highlighted guidance on transfusion therapy, disease-specific screening practices, and consistent monitoring and treatment of therapy-related side effects, particularly iron overload.
What was the broader intent beyond developing clinical protocols?
Beyond clinical protocols, the opportunity emphasized access to care: developing approaches that assure access to comprehensive services and improving availability of specialty providers and coordinated care models for thalassemia patients.
Browse more opportunities from the same category: Health
Next opportunity: National Hemophilia Program Coordinating Center
Previous opportunity: Predation Rates and Use of Habitats and Wildlife Drinkers by Mountain Lions
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for HRSA 15 079
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (HRSA 15 079) also looked into and applied for these:
| Funding Opportunity |
|---|
| National Hemophilia Program Coordinating Center Apply for HRSA 15 087 Funding Number: HRSA 15 087 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Effectiveness of Teen Pregnancy Prevention Programs Designed Specifically for Young Males Apply for RFA DP 15 007 Funding Number: RFA DP 15 007 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Nurse Faculty Loan Program (NFLP) Apply for HRSA 15 049 Funding Number: HRSA 15 049 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Improving Surveillance and Prevention of Epilepsy Burden in US Communities Apply for RFA DP 15 009 Funding Number: RFA DP 15 009 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
| Population Based Birth Defects Surveillance and Utilization of Surveillance Data by Public Health Programs Apply for CDC RFA DD15 1508 Funding Number: CDC RFA DD15 1508 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Sentinel Enhanced Dengue Surveillance System (SEDSS) Sites to Evaluate the Epidemiology and Prevention of Dengue and other Acute Febrile Illnesses in Puerto Rico Apply for RFA CK 15 002 Funding Number: RFA CK 15 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $600,000 |
| Detection and Characterization of Emerging Vector Borne Zoonotic Apply for RFA CK 15 001 Funding Number: RFA CK 15 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $550,000 |
| Capacity Building to Prevent, Detect, and Respond to Emerging Infectious Disease Threats and Strengthen Global Health Security in Uganda Apply for RFA CK 15 003 Funding Number: RFA CK 15 003 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,500,000 |
| Continuing Prospective Birth Cohort Study Involving Environmental Uranium Exposure in the Navajo Nation Apply for RFA TS 13 0010501SUPP15 Funding Number: RFA TS 13 0010501SUPP15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $360,000 |
| Suicide Prevention Resource Center (SPRC) Apply for SM 15 003 Funding Number: SM 15 003 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $5,634,000 |
| Economic Studies of Immunization Policies and Practices Apply for RFA IP 15 001 Funding Number: RFA IP 15 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
| MCH Pediatric Research Network Program Apply for HRSA 15 089 Funding Number: HRSA 15 089 Agency: Health Resources and Services Administration Category: Health Funding Amount: $200,000 |
| Maternal and Child Health Epidemiology Doctoral Training Program Apply for HRSA 15 109 Funding Number: HRSA 15 109 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Maternal and Child Health (MCH) Research Network on Pregnancy Related Care Program Apply for HRSA 15 090 Funding Number: HRSA 15 090 Agency: Health Resources and Services Administration Category: Health Funding Amount: $400,000 |
| Regional AIDS Education and Training Centers Apply for HRSA 15 032 Funding Number: HRSA 15 032 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| AETC National Coordinating Resource Center (NCRC) Cooperative Agreement Apply for HRSA 15 033 Funding Number: HRSA 15 033 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Conducting Public Health Research in Kenya Apply for RFA GH 15 001 Funding Number: RFA GH 15 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $15,000,000 |
| Grants to States to Support Oral Health Workforce Activities Apply for HRSA 15 052 Funding Number: HRSA 15 052 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) Apply for PAR 15 084 Funding Number: PAR 15 084 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIA Academic Leadership Career Award (K07) Apply for PAR 15 078 Funding Number: PAR 15 078 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "HRSA 15 079", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.